Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study.
Saved in:
| Title: | Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. |
|---|---|
| Authors: | Lin, Min‐Hsi1,2 (AUTHOR), Chu, Kuo‐An1,3 (AUTHOR), Chen, Chiu‐Fan1 (AUTHOR), Jiang, You‐Cheng1 (AUTHOR), Hong, Wei‐Cheng1 (AUTHOR), Hung, Ming‐Yen1 (AUTHOR), Hsu, Chun‐Hsiang1,4 (AUTHOR) benhsu740124@gmail.com |
| Source: | Cancer Medicine. May2026, Vol. 15 Issue 5, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 194013557 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Lin%2C+Min‐Hsi%22">Lin, Min‐Hsi</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chu%2C+Kuo‐An%22">Chu, Kuo‐An</searchLink><relatesTo>1,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+Chiu‐Fan%22">Chen, Chiu‐Fan</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jiang%2C+You‐Cheng%22">Jiang, You‐Cheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hong%2C+Wei‐Cheng%22">Hong, Wei‐Cheng</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hung%2C+Ming‐Yen%22">Hung, Ming‐Yen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hsu%2C+Chun‐Hsiang%22">Hsu, Chun‐Hsiang</searchLink><relatesTo>1,4</relatesTo> (AUTHOR)<i> benhsu740124@gmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Cancer+Medicine%22">Cancer Medicine</searchLink>. May2026, Vol. 15 Issue 5, p1-11. 11p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=194013557 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cam4.71881 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 11 StartPage: 1 Titles: – TitleFull: Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lin, Min‐Hsi – PersonEntity: Name: NameFull: Chu, Kuo‐An – PersonEntity: Name: NameFull: Chen, Chiu‐Fan – PersonEntity: Name: NameFull: Jiang, You‐Cheng – PersonEntity: Name: NameFull: Hong, Wei‐Cheng – PersonEntity: Name: NameFull: Hung, Ming‐Yen – PersonEntity: Name: NameFull: Hsu, Chun‐Hsiang IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: May2026 Type: published Y: 2026 Identifiers: – Type: issn-print Value: 20457634 Numbering: – Type: volume Value: 15 – Type: issue Value: 5 Titles: – TitleFull: Cancer Medicine Type: main |
| ResultId | 1 |